Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apalutamide and Cetrelimab in t-SCNC Prostate Cancer
NCT04926181Phase 2Terminated
- Sponsor
- Rahul Aggarwal
- Start
- Mar 2022
- Primary completion
- Mar 2024
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of cetrelimab in small cell neuroendocrine carcinoma of the prostate (SCPC), sponsored by Rahul Aggarwal. Started Mar 2022; status: terminated.
02
Drugs
cetrelimab
03
Conditions
small cell neuroendocrine carcinoma of the prostate (SCPC)
Beyond the preview
Go deeper on NCT04926181.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04926181.